FDA report cites risks of anemia drugs for cancer patients

An FDA staff report raised concerns about risks to cancer patients from anemia drugs such as Amgen's Aranesp and Johnson & Johnson's Procrit. The FDA cited results from five trials showing decreased survival times for patients receiving the drugs, compared with patients getting blood transfusions. An advisory panel is scheduled to meet Thursday to consider stricter labeling for the drugs.

View Full Article in:

Los Angeles Times (tiered subscription model) · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID